8-K
Bio-Techne Declares Quarterly Dividend of $0.08 Per Share
8-K
Bio-Techne Shareholders Approve Acquisition by Merck KGaA
8-K
Bio-Techne Files Form 8-K Describing Merger-Related Litigation and Providing Supplemental Proxy Disclosures
8-K
Bio-Techne Reports Fourth Quarter Fiscal 2026 Results and Progress on Merck KGaA Acquisition
8-K
Bio-Techne Corporation to be Acquired by Merck KGaA for $73.00 Per Share
8-K
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne for US$11.3 Billion